Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspire Health vs Kova

Aspire Health
Graded #346

Higher grade

vs+14.900000000000006
Kova
Graded #498

Lower grade

The verdict

Aspire Health takes it — 59.2/100 to 44.3/100.

Aspire Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aspire Health is a Nebraska-based telehealth practice offering both compounded semaglutide/tirzepatide (formulated with B6) and brand-name Wegovy and Zepbound, prescribed by a named PA/NP clinical team.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAspire Health +25
45
20
Dose & formulationAspire Health +13
53
40
Clinical oversightAspire Health +13
84
71
Labs & monitoringAspire Health +14
66
52
FulfillmentEven
61
61
Contract termsAspire Health +16
41
25
Aspire Health · left barKova · right bar

The numbers

MetricAspire HealthKova
WeighScore59.2/10044.3/100
GradeCC
Scorecard rank#346#498
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Aspire Health

Graded #346 · C

Strengths

  • Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
  • Lab orders with interpretation included in LoseIt membership — not billed separately
  • Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
  • Slimpossible app + secure messaging for ongoing support between provider visits
  • HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans

Where it loses points

  • Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
  • No LegitScript certification or independent third-party accreditation disclosed
  • States served not publicly listed; availability depends on individual provider licensure
  • All medication sales are final once shipped; consultation fee non-refundable once completed
  • Compounding pharmacy partner not named on any public page
Kova

Graded #498 · C

Strengths

  • Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
  • Medication is included in the plan price, with no separate pharmacy charge
  • States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
  • Companion app tracks weight, protein and side effects, with medication schedule reminders
  • You are not charged unless a provider approves treatment

Where it loses points

  • At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
  • The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
  • Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
  • Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
  • No pharmacy or prescribing medical group is named anywhere on the site

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard